Skip to main content

Day: June 9, 2020

 CanWel Building Materials Announces National Distribution Partnership With CertainTeed Canada

NOT FOR RELEASE OR DISSEMINATION INTO THE UNITED STATESVANCOUVER, British Columbia, June 09, 2020 (GLOBE NEWSWIRE) — CanWel Building Materials Group Ltd. (“CanWel” or “the Company”) (TSX:CWX; CWX.NT.A) is pleased to announce that effective immediately its CanWel Building Materials Division has entered into a multi-year partnership with CertainTeed Canada for the distribution of its glass mineral wool insulation products to the Lumber, Building Materials (LBM) and OEM channels across Canada. CertainTeed Canada is one of the world leaders in manufacturing and sales of sustainable glass mineral wool insulation. CanWel will extend its product offering for the LBM channel to include this high quality product line and to partner with one of the world’s largest manufacturers of glass mineral wool insulation.CanWel’s national stocking...

Continue reading

Dynavax Completes Enrollment of Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

The trial enrolled 119 patients with end-stage renal disease undergoing hemodialysisFinal immunogenicity data anticipated in Q4 2020EMERYVILLE, Calif., June 09, 2020 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has completed enrollment of 119 patients in the clinical trial evaluating HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] in adults with end-stage renal disease (ESRD) who are initiating or undergoing hemodialysis. The Company anticipates final immunogenicity study data in the fourth quarter of 2020.“Completing patient enrollment for this study is a significant milestone for our company,” commented Robert Janssen, MD, Chief Medical Officer at Dynavax. “We are evaluating a 4-dose regimen...

Continue reading

Press Release Oncology Venture is issuing 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Hørsholm, Denmark, June 9th, 2020 – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) today announces that it will issue 751,879 shares at a price per share of SEK 1.33 to Negma Group LTD.The share issue is carried out pursuant to the convertible note agreement with Negma Group LTD and Park Partners GB.Oncology Venture announced on April 3rd, 2020, that it has called upon the first tranche of convertible notes of SEK 10 million in line with the terms from the financing agreement communicated on March 31st, 2020. Negma Group Ltd. has today requested to convert SEK 1,000,000 of the notes into 751,879 shares of nominal DKK 0.05 each.The conversion price is fixed at SEK 1.33 per share of nominal DKK 0.05 share and has been calculated as 95% of the lowest VWAP share price of the seven consecutive trading days...

Continue reading

Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (letermovir) From AiCuris Anti-Infective Cures GmbH

NEW YORK and WUPPERTAL, Germany, June 09, 2020 (GLOBE NEWSWIRE) — Royalty Pharma and AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced today that they have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time payment of $220 million. Prevymis is licensed by MSD, the tradename of Merck & Co. Inc., Kenilworth, NJ, USA.The product was approved by the US Food & Drug Administration (FDA) in 2017 and by the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in 2018 for prophylaxis (prevention) of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant...

Continue reading

Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series

MONMOUTH JUNCTION, N.J., June 09, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at the Virtual Investor Fireside Chat Series on Wednesday, June 17, 2020 at 2:00 PM ET.A live video webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website (outlooktherapeutics.com). Immediately following the fireside chat, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will...

Continue reading

Microchip Introduces 3 kW Transient Voltage Suppressor Diode Array Family for Superior Circuit Protection in Harsh Environments

CHANDLER, Ariz., June 09, 2020 (GLOBE NEWSWIRE) — To ensure critical operations, aviation and space systems rely on digital and logic functionality and circuitry in engine control units, environmental controls, instruments and actuators. Data centers, the 5G infrastructure and communication systems also rely on complex circuitry requiring protection. Each system must operate continuously despite voltage surges and spikes from lightning, solar events and electromagnetic incidents. Microchip Technology Inc. (Nasdaq: MCHP) today announced its newly-expanded portfolio of Transient Voltage Suppressor (TVS) vertical arrays – the MDA3KP Transient Voltage Suppressor (TVS), a 3 kW diode family of more than 25 products with different screening levels, polarities and qualification standards.Microchip’s MDA3KP TVS diode array family – the only...

Continue reading

Proofpoint Launches New Enterprise Archiving Innovations Across eDiscovery and Compliance Supervision

SUNNYVALE, Calif., June 09, 2020 (GLOBE NEWSWIRE) — Proofpoint, Inc., (NASDAQ: PFPT), a leading cybersecurity and compliance company, today announced numerous enhancements to its award-winning Proofpoint Enterprise Archive solution to help customers streamline e-discovery and supervision processes and reduce related costs. Deployed by top organizations worldwide, Proofpoint Enterprise Archive is a proven, cloud-native, modern archiving solution that delivers unmatched search performance, supported by an industry-leading and financially backed service level agreement (SLA).“Proofpoint has been recognized by Gartner as a Leader in the Magic Quadrant for Enterprise Information Archiving for eight consecutive years and we believe today’s advancements are the latest example of our commitment to ongoing innovation,” said Darren Lee, executive...

Continue reading

Royale Completes Two North Jameson Wells

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) — Royale Energy, Inc., (OTCQB : ROYL), an independent exploration and production company based in San Diego, California announces that it has completed and put into production two new vertical low cost oil wells in its North Jameson field in the Permian Basin in Nolan County, Texas.The McCabe #61 was completed in the Strawn formation pumping at a rate of 106 barrels of oil per day, 40 MCF per day and no water. The well has 25 ft. of net oil pay.The McCabe #62 has been completed in the Odom formation pumping at a rate of 110 barrels of oil per day. The Odom formation has 24 ft. of net oil pay.McCabe #62 was drilled as an infill evaluation of the Odom and Strawn. The Strawn formation has 21 ft. of net oil pay and will remain behind pipe for a future completion. The well also encountered 27...

Continue reading

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A sessionROCHESTER, N.Y., June 09, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease and cancer, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex will present at the Virtual Investor Fireside Chat Series on Tuesday, June 16, 2020 at 10:00 AM ET.A live video webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website (www.vaccinex.com). Immediately following the fireside chat, management will participate in an interactive Q&A session with interested...

Continue reading

Teledyne Princeton Instruments introduces Raman spectrometer for limitation-shattering, high-sensitivity performance in NIR

TRENTON, N.J, June 09, 2020 (GLOBE NEWSWIRE) — Teledyne Princeton Instruments, a Teledyne Technologies [NYSE:TDY] company,  and world-renowned manufacturer of scientific imaging and spectroscopy equipment, is pleased to introduce its new TPIR-785 Raman spectrometer, a fully integrated system that leverages leading-edge spectrograph and camera technologies to optimize performance in the near-infrared (NIR) region. The TPIR-785 is an ultra-high-sensitivity spectrometer for NIR Raman spectroscopic application areas such as biology, medical research and life science where NIR excitation lasers (785 nm and 830 nm) are preferred for their low fluorescence and deeper penetration depth when measuring biological tissues.This new system utilizes an f/2 spectrograph with custom-designed lens optics to provide the highest light throughput and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.